Published in Risk Anal on April 01, 2005
Communicating the results of clinical research to participants: attitudes, practices, and future directions. PLoS Med (2008) 3.05
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Effect of communicating DNA based risk assessments for Crohn's disease on smoking cessation: randomised controlled trial. BMJ (2012) 1.51
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol (2009) 1.37
Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med (2008) 1.20
"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med (2010) 1.19
Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding. Genome Med (2014) 1.08
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med (2008) 1.08
A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol (2013) 1.03
Self-rated cardiovascular risk and 15-year cardiovascular mortality. Ann Fam Med (2008) 1.02
"It's not like judgment day": public understanding of and reactions to personalized genomic risk information. J Genet Couns (2011) 1.01
The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet (2010) 0.98
Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test (2008) 0.89
Trial Protocol: Communicating DNA-based risk assessments for Crohn's disease: a randomised controlled trial assessing impact upon stopping smoking. BMC Public Health (2011) 0.81
Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. Alzheimers Res Ther (2016) 0.76
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 5.55
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet (2002) 3.60
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol (2002) 2.86
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res (2012) 2.76
Point-counterpoint. Ethics and genomic incidental findings. Science (2013) 2.73
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med (2004) 2.44
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med (2013) 2.08
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
Direct to consumer genetic testing: Avoiding a culture war. Genet Med (2009) 2.00
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) (2005) 1.93
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Methodological Considerations in Studying Centenarians: Lessons Learned From the Georgia Centenarian Studies. Annu Rev Gerontol Geriatr (2007) 1.85
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry (2011) 1.83
Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.79
Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol (2006) 1.78
Trail Making Test errors in normal aging, mild cognitive impairment, and dementia. Arch Clin Neuropsychol (2008) 1.69
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68
Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) (2010) 1.67
Panton valentine leukocidin (PVL) toxin positive MRSA strains isolated from companion animals. Vet Microbiol (2005) 1.66
Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology (2013) 1.63
Regulation: The FDA is overcautious on consumer genomics. Nature (2014) 1.52
Epidemiology of apathy in older adults: the Cache County Study. Am J Geriatr Psychiatry (2007) 1.50
Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med (2016) 1.47
Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care (2012) 1.46
The future of direct-to-consumer clinical genetic tests. Nat Rev Genet (2011) 1.38
Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol (2002) 1.37
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement (2011) 1.35
The adult galactosemic phenotype. J Inherit Metab Dis (2011) 1.34
Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci (2009) 1.33
Clock drawing test ratings by dementia specialists: interrater reliability and diagnostic accuracy. J Neuropsychiatry Clin Neurosci (2010) 1.33
Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet (2013) 1.33
A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol (2011) 1.33
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. Proc Natl Acad Sci U S A (2013) 1.26
Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns (2006) 1.26
Cognitive correlates of HVOT performance differ between individuals with mild cognitive impairment and normal controls. Arch Clin Neuropsychol (2006) 1.26
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26
Development and validation of a computational method for assessment of missense variants in hypertrophic cardiomyopathy. Am J Hum Genet (2011) 1.25
Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr (2010) 1.25
Diagnostic clinical genome and exome sequencing. N Engl J Med (2014) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County Study. Am J Geriatr Psychiatry (2005) 1.23
Differences between African Americans and whites in their perceptions of Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.21
Clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus in pregnancy. Obstet Gynecol (2005) 1.21
"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med (2010) 1.19
Lower-extremity function in cognitively healthy aging, mild cognitive impairment, and Alzheimer's disease. Arch Phys Med Rehabil (2010) 1.18
Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med (2005) 1.17
The beliefs, motivations, and expectations of parents who have enrolled their children in a genetic biorepository. Genet Med (2012) 1.17
Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. Genet Test (2003) 1.16
Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch Neurol (2008) 1.16
A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis Assoc Disord (2009) 1.16
A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Med Genet (2014) 1.14
Health-care referrals from direct-to-consumer genetic testing. Genet Test Mol Biomarkers (2010) 1.13
Navigating a research partnership between academia and industry to assess the impact of personalized genetic testing. Genet Med (2012) 1.11
Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet (2005) 1.08
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genet Med (2008) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol (2005) 1.07
Test-retest stability on the WRAT-3 reading subtest in geriatric cognitive evaluations. J Clin Exp Neuropsychol (2008) 1.06
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers (2011) 1.06
Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res (2013) 1.03
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr (2005) 1.03
Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med (2006) 1.03
The Framingham Brain Donation Program: neuropathology along the cognitive continuum. Curr Alzheimer Res (2012) 1.02
Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet (2014) 1.02
Heritability of magnetic resonance imaging (MRI) traits in Alzheimer disease cases and their siblings in the MIRAGE study. Alzheimer Dis Assoc Disord (2007) 1.02
Diagnostic utility of the NAB List Learning test in Alzheimer's disease and amnestic mild cognitive impairment. J Int Neuropsychol Soc (2009) 1.02
GINA, genism, and civil rights. Bioethics (2008) 1.02
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement (2008) 1.00
Education effects on cognitive function in a healthy aged Arab population. Int Psychogeriatr (2006) 1.00
Magnetic resonance imaging traits in siblings discordant for Alzheimer disease. J Neuroimaging (2008) 0.99
Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am J Hum Genet (2016) 0.99
The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet (2010) 0.98
Geriatric performance on an abbreviated version of the Boston naming test. Appl Neuropsychol (2007) 0.97
Research results: preserving newborn blood samples. Sci Transl Med (2012) 0.97
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A (2012) 0.95
Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease. Genet Med (2012) 0.95
Clock drawing performance in cognitively normal elderly. Arch Clin Neuropsychol (2008) 0.94
How Well Do Customers of Direct-to-Consumer Personal Genomic Testing Services Comprehend Genetic Test Results? Findings from the Impact of Personal Genomics Study. Public Health Genomics (2015) 0.93
Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study. Int Psychogeriatr (2012) 0.92
A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics (2015) 0.92
Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol (2008) 0.91
Design of a randomized trial of diabetes genetic risk testing to motivate behavior change: the Genetic Counseling/lifestyle Change (GC/LC) Study for Diabetes Prevention. Clin Trials (2011) 0.91
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med (2011) 0.90
Management of incidental findings in clinical genomic sequencing. Curr Protoc Hum Genet (2013) 0.90
Maternal sepsis. Obstet Gynecol Clin North Am (2013) 0.90
Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer's disease. J Genet Couns (2008) 0.89